Clinical Trial: A Phase 2A Trial of MM402 for Autism Spectrum Disorder

U.S., Dec. 27 -- ClinicalTrials.gov registry received information related to the study (NCT07303907) titled 'A Phase 2A Trial of MM402 for Autism Spectrum Disorder' on Dec. 22.

Brief Summary: A Phase 2A Trial of MM402 Open-Label Study in Adults with Autism Spectrum Disorder

Study Start Date: Dec. 03

Study Type: INTERVENTIONAL

Condition: Autism Spectrum Disorder ASD

Intervention: DRUG: MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA))

A psychoactive substance that mediates effects mainly through a release of the monoaminergic neurotransmitters, with the greatest effect on 5-HT, followed by NE and DA

Recruitment Status: RECRUITING

Sponsor: Mind Medicine, Inc.

Disclaimer: Curated by HT Syndication....